Literature DB >> 15897577

Cyclooxygenase-2 overexpression is associated with a poor outcome in resected ampullary cancer patients.

Daniele Santini1, Bruno Vincenzi, Giuseppe Tonini, Susanna Scarpa, Fortunata Vasaturo, Carolina Malacrino, Fabio Vecchio, Domenico Borzomati, Sergio Valeri, Roberto Coppola, Paolo Magistrelli, Gennaro Nuzzo, Aurelio Picciocchi.   

Abstract

PURPOSE: To identify potential prognostic molecular factors in ampullary adenocarcinoma that could be of significant importance. To this end, we examined the possible prognostic significance of cyclooxygenase-2 (Cox-2) and Survivin expression and the apoptotic index in a cohort of uniformly treated patients with ampullary cancer treated with radical surgical excision. EXPERIMENTAL
DESIGN: The entry criteria were that the patients have a pathologic diagnosis of ampullary cancer which had been resected. Expression analysis for Cox-2 and Survivin was done by immunohistochemical staining. Apoptotic cells were identified by the terminal deoxyribonucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) method.
RESULTS: Thirty-nine tumor specimens from resected ampullary adenocarcinoma patients were included. By univariate analysis, overall survival was affected by Cox-2 expression and TUNEL staining (respectively, P = 0.0003 and 0.03). Survivin expression did not influence the overall survival in our patient population (P = 0.123). Patients' clinicopathologic features (gender, age, and T and N factors) did not influence outcome. In multivariate Cox regression analysis, Cox-2 expression (relative risk, 4.330; P = 0.005) was the only variable that significantly affected overall survival.
CONCLUSIONS: The results of the present article provide, for the first time, evidence that Cox-2 expression, but not Survivin expression, may represent a significant prognostic factor after surgical resection in patients affected by cancer of the ampulla of Vater. Further studies are required to determine whether Cox-2 inhibitors may be useful for the therapy or prevention of ampullary carcinoma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15897577     DOI: 10.1158/1078-0432.CCR-04-2136

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  7 in total

1.  Inflammation and cancer.

Authors:  Noemí Eiró; Francisco J Vizoso
Journal:  World J Gastrointest Surg       Date:  2012-03-27

Review 2.  Inflammation and cancer: how friendly is the relationship for cancer patients?

Authors:  Bharat B Aggarwal; Prashasnika Gehlot
Journal:  Curr Opin Pharmacol       Date:  2009-08-06       Impact factor: 5.547

3.  COX-2 expression of ampullary carcinoma: correlation with different histotypes and clinicopathological parameters.

Authors:  Giuseppe Perrone; Daniele Santini; Mariagiovanna Zagami; Bruno Vincenzi; Alfio Verzì; Sergio Morini; Domenico Borzomati; Roberto Coppola; Armando Antinori; Paolo Magistrelli; Giuseppe Tonini; Carla Rabitti
Journal:  Virchows Arch       Date:  2006-08-12       Impact factor: 4.064

4.  Clinical significance of Cox-2, Survivin and Bcl-2 expression in hepatocellular carcinoma (HCC).

Authors:  Yu Yang; Jiang Zhu; Hongfeng Gou; Dan Cao; Ming Jiang; Mei Hou
Journal:  Med Oncol       Date:  2010-04-17       Impact factor: 3.064

5.  Human equilibrative nucleoside transporter 1 and carcinoma of the ampulla of Vater: expression differences in tumour histotypes.

Authors:  G Perrone; S Morini; D Santini; C Rabitti; B Vincenzi; R Alloni; A Antinori; P Magistrelli; R Lai; C Cass; J R Mackey; R Coppola; G Tonini; A Onetti Muda
Journal:  Eur J Histochem       Date:  2010       Impact factor: 3.188

6.  COX-2 overexpression in resected pancreatic head adenocarcinomas correlates with favourable prognosis.

Authors:  Ewa Pomianowska; Aasa R Schjølberg; Ole Petter F Clausen; Ivar P Gladhaug
Journal:  BMC Cancer       Date:  2014-06-20       Impact factor: 4.430

7.  Impact of Standardized Allergen-Removed Rhus verniciflua Stokes Extract on Advanced Adenocarcinoma of the Ampulla of Vater: A Case Series.

Authors:  Woncheol Choi; Soomin An; Eunmi Kwon; Wankyu Eo; Sanghun Lee
Journal:  Evid Based Complement Alternat Med       Date:  2013-04-22       Impact factor: 2.629

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.